argenx SE (ARGX) Stock: Price, Forecast & Analyst Target
argenx SE (ARGX) — MoonshotScore 96/100 (Exceptional band), calculated Nov 18, 2026. Price $942.04 (+0.08%), as of the Nov 19, 2026 trading session; market cap $59.2B. Expected results Feb 25, 2027.
Educational signal · not a buy or sell recommendation · How to read this
argenx SE · ARGX · NASDAQ · Healthcare · Biotechnology
Research dated 2026-09-12: argenx is a commercial autoimmune-drug company built around efgartigimod and the VYVGART family, with a wider antibody pipeline behind it. Its results now reflect a profitable medicine franchise rather than the cash burn usually associated with an early biotechnology developer. Franchise durability depends on whether VYVGART adoption and additional indications can outrun rising commercialization and research costs.
Price as of Nov 19, 2026
Key Statistics
MoonshotScore v2 · argenx SE (ARGX)
ExceptionalWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Elite quality, a fortress balance sheet and elite growth, but an expensive valuation; the market is already moving on it. The score also carries a risk penalty for reported profit not backed by cash flow. Business Quality: Elite; Financial Safety: Fortress; Valuation: Rich; Growth Durability: Compounding; Momentum: Surging.
- EPS beat 1 of the last 4 reports
- Altman Z 21.94 · Piotroski F 4
Helping: business quality, balance-sheet strength, durable growth, positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 96 | Exceptional | |
| 96 | Exceptional | |
| 96 | Exceptional | |
| 96 | Exceptional | |
| 96 | Exceptional | |
| 96 | Exceptional |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $942.04 | |
| Change on the day | +0.08% | |
| 52-week range | $661.85–$1072.75 | |
| Market capitalisation | $59.2B | — |
| Price / earnings (trailing) | 44.14 | |
| Shares traded on the day | 283.4K | |
| Beta (volatility vs the S&P 500) | -0.02 |
Price & events
Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file. Numbers key to the dated list. Point at or tab to any week for its close.
Events behind the price
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.
Upcoming events
How to read these dates
Estimated dates can change.
Other perspectives
Council score for argenx SE (ARGX): perspectives
Some lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.
5-Factor Breakdown
Legends Council
5 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 19, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation
Read on: Nov 19, 2026
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
One of these lenses reads this company less favourably than the MoonshotScore does: Munger lens (margin of safety). Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.
The Munger lens reads the current price as overvalued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is argenx SE (ARGX), and what does it report?
Short answer · as of
argenx develops antibody therapies for autoimmune disease, but it is no longer defined mainly by clinical research.
Research dated 2026-09-12.
VYVGART and related efgartigimod formulations form the commercial core, while empasiprubart, ARGX compounds and other programs extend the development portfolio across neurology, rheumatology and inflammatory disease.
Reported revenue, gross profit and earnings therefore measure a companywide commercial franchise supporting a broad pipeline, not progress in laboratory programs by itself. The shift from deep losses to substantial profit is the clearest evidence that argenx has crossed from development-led biotechnology into commercial biopharma.
What do the latest results show for argenx SE (ARGX)?
Research dated 2026-09-12.
Revenue and net income eased from the unusually high preceding listed period, while operating profit remained near its prior level despite a sharp increase in commercial spending. Operating cash generation strengthened further, leaving the latest period far ahead of the cash-consuming profile visible in the older results.
The longer trend remains expansion rather than contraction: annual revenue rose sharply, losses became profits and research spending continued to climb. VYVGART and efgartigimod anchor that commercial and development scale, while management presents myositis as a bridge into a broader rheumatology presence. That statement describes strategic intent; the eventual clinical readout must establish whether the opportunity is real.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Sep 30, 2026 | Not available | Not available | Not available | Not available |
| Jun 30, 2026 | Not available | Not available | Not available | Not available |
| Mar 31, 2026 | Not available | Not available | Not available | Not available |
| Dec 31, 2025 | Not available | Not available | Not available | Not available |
How to read these figures
Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.
Did results meet expectations?
Reported earnings and revenue alongside the estimates recorded by the provider.
- Latest report · revenue
- $2.82B Jul 30, 2026
- Latest report · revenue estimate
- $1.66B Jul 30, 2026
- Latest report · revenue vs estimate
- Above estimate Jul 30, 2026
- Latest report · EPS vs estimate
- Above estimate Jul 30, 2026
| Report date | Revenue · reported | Revenue · estimate | EPS · reported | EPS · estimate |
|---|---|---|---|---|
| Jul 30, 2026 | $2.82B | $1.66B | $7.8000 | $7.4400 |
| May 7, 2026 | $3.21B | $1.45B | $5.9000 | $5.1600 |
| Oct 30, 2025 | $947.96M | $1.28B | $5.1800 | $4.3700 |
| May 8, 2025 | $573.24M | $861.83M | $2.5800 | $2.3200 |
How to read these figures
Dates are when results were reported, not quarter ends. Amounts are in US dollars; EPS is per share. The source does not say whether EPS is basic, diluted or adjusted, so it can differ from the EPS in the income statement.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Sep 2025 | $1.13B | $344M | $5.18 (diluted) |
| Q4 FY2025 | $1.29B | $533M | — |
| Mar 2026 | $1.30B | $366M | $5.52 (diluted) |
| Q2 FY2026 | $1.51B | $472M | — |
What are the financial strengths and risks for argenx SE (ARGX)?
Short answer · as of
Cash and short-term investments were $0.00 at the Jun 30, 2026 balance-sheet date. This figure does not establish a cash runway.
Research dated 2026-09-12.
argenx combines substantial cash and investments with little debt, ample short-term coverage and a cash balance that has risen alongside operating cash generation. Capital expenditure remains modest, so the commercial franchise has recently converted sales into cash without requiring heavy physical investment.
The larger risk lies in expectations and concentration rather than financing. Market value stands far above net cash, valuation multiples remain demanding and forecasts embed continued revenue and earnings growth. Because efgartigimod and VYVGART sit at the center of the portfolio, weaker treatment adoption, disappointing indication expansion or commercial costs rising faster than gross profit would challenge that growth profile.
Data-derived red flags
- Inconsistent delivery — missed Wall Street EPS estimates in 0 of the last 4 reported quarters.
- Rich valuation — a P/E of 44.14 runs well above the Healthcare sector’s ~21.70x, leaving little room for a miss.
What should you watch next at argenx SE (ARGX)?
Short answer · as of
The next earnings report is expected on Feb 25, 2027.
Research dated 2026-09-12.
VYVGART demand is the immediate checkpoint. Compare reported revenue with the preceding period and external expectations, then test whether gross profit and operating income keep pace as commercialization spending expands; recent earnings history shows that revenue outcomes can diverge materially from expectations even when earnings are stronger.
Cash conversion deserves equal attention because the balance sheet has been reinforced by operating inflows rather than debt. A sustained reversal in operating cash flow alongside rising research or commercial expense would weaken an important financial advantage.
Myositis is the pipeline checkpoint with strategic reach beyond the current franchise. Management has tied that program to broader rheumatology ambitions, so the clinical result matters not merely as another indication but as evidence for extending the efgartigimod platform into a wider specialist market.
What the records here don't tell us
- No forward revenue or earnings estimate is on file.
- No insider Form 4 transaction falls inside the window this page reads.
Checked against the records this page reads, on the dates shown above.
How does argenx SE compare with its peers?
Short answer
argenx SE's score ranks tied for 3rd of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
Research dated 2026-09-12.
argenx occupies the space between development-stage biotechnology and diversified pharmaceutical companies. Unlike clinical-stage peers, it already produces substantial revenue, profit and operating cash; unlike diversified drugmakers, its economic center remains closely tied to efgartigimod and the VYVGART franchise.
Its cash-rich, lightly levered and capital-light profile makes near-term financing less defining than treatment adoption and clinical expansion. That combination offers direct exposure to a successful autoimmune platform, but with less product diversification than a broad pharmaceutical portfolio.
| Company | Price | Market value | Score |
|---|---|---|---|
| $65.83 Nov 19, 2026 | $16.1B | 98 5-pillar Nov 18, 2026 | |
| $577.34 Nov 18, 2026 | $24.6B | 97 5-pillar Nov 18, 2026 | |
| argenx SE (ARGX) — this page | $942.04 | $59.2B | 96 |
| $689.65 Nov 19, 2026 | $54.3B | 96 5-pillar Nov 18, 2026 | |
| $270.33 Nov 18, 2026 | $17.7B | 96 5-pillar Nov 18, 2026 | |
| $945.53 Nov 18, 2026 | $97.8B | 95 5-pillar Nov 18, 2026 | |
| $162.86 Nov 18, 2026 | $16.5B | 95 5-pillar Nov 18, 2026 | |
| $105.23 Nov 18, 2026 | $60.5B | 93 5-pillar Nov 18, 2026 | |
| $117.80 Nov 18, 2026 | $24.0B | 91 5-pillar Nov 18, 2026 | |
| $536.45 Nov 18, 2026 | $136B | 90 5-pillar Nov 18, 2026 | |
| $272.37 Nov 19, 2026 | $63.0B | 88 5-pillar Nov 18, 2026 | |
| $39.43 Nov 18, 2026 | $174B | 87 5-pillar Nov 18, 2026 | |
| $68.67 Nov 18, 2026 | $39.5B | 73 5-pillar Nov 18, 2026 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $861.00 – $1400.00
- Consensus target
- $1152.06
- Median target
- $1150.00
Consensus record · Captured .
Measured against a quoted price of $942.04 (as of Nov 19, 2026).
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held ARGX in their latest 13F filing, and what they did against the filing before it.
| Investor | Manager | 13F quarter | Portfolio weight | Value | Last quarter |
|---|---|---|---|---|---|
| Bridgewater Associates | Founded by Ray Dalio | Q3 2026 | 0.09% | $20.94M | Added +1015.5% shares |
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about argenx SE (ARGX)?
ARGX Healthcare Stock FAQ
Research dated 2026-09-12; the full attribution is under Sources. The last 2 questions are answered from this page's own dated data, not from the research.
How does VYVGART turn patient adoption into argenx revenue?
VYVGART is the commercial expression of the efgartigimod platform, so revenue follows treatment use across eligible autoimmune populations and geographic markets. Additional indications can widen those patient pools, while weaker uptake would pressure the franchise financing the broader pipeline.
Why is argenx using myositis to reach rheumatology?
Management presents a myositis launch as the foundation for a broader rheumatology presence. The clinical readout therefore tests whether efgartigimod can extend beyond its established autoimmune applications into another specialist market.
Can VYVGART cash generation fund the argenx pipeline?
Recent periods show substantial positive operating cash flow, rising liquidity and continued research investment, giving argenx meaningful capacity to fund development internally. Continued support depends on commercial cash generation keeping pace with research and commercialization costs.
What makes argenx unlike a clinical-stage FcRn company?
argenx already has a profitable commercial franchise and substantial operating cash generation around VYVGART, while continuing to develop efgartigimod and other antibody candidates. Its risk has shifted from financing research toward sustaining adoption and proving that the platform can support additional indications.
What is the ARGX stock price today?
The last price recorded for argenx SE (ARGX), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the ARGX price target?
The analyst consensus price target for argenx SE (ARGX), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
Research written by Codex (gpt-5.6-sol) on 2026-09-12. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 41 figures on this page — 1 from SEC filings and earnings calls, 35 from Financial Modeling Prep (FMP), 2 with no recorded source, 2 computed by us, formula shown in the register and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com